These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 25609060)

  • 1. Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma.
    Di Stefano AL; Fucci A; Frattini V; Labussiere M; Mokhtari K; Zoppoli P; Marie Y; Bruno A; Boisselier B; Giry M; Savatovsky J; Touat M; Belaid H; Kamoun A; Idbaih A; Houillier C; Luo FR; Soria JC; Tabernero J; Eoli M; Paterra R; Yip S; Petrecca K; Chan JA; Finocchiaro G; Lasorella A; Sanson M; Iavarone A
    Clin Cancer Res; 2015 Jul; 21(14):3307-17. PubMed ID: 25609060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transforming fusions of FGFR and TACC genes in human glioblastoma.
    Singh D; Chan JM; Zoppoli P; Niola F; Sullivan R; Castano A; Liu EM; Reichel J; Porrati P; Pellegatta S; Qiu K; Gao Z; Ceccarelli M; Riccardi R; Brat DJ; Guha A; Aldape K; Golfinos JG; Zagzag D; Mikkelsen T; Finocchiaro G; Lasorella A; Rabadan R; Iavarone A
    Science; 2012 Sep; 337(6099):1231-5. PubMed ID: 22837387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Varied histomorphology and clinical outcomes of FGFR3-TACC3 fusion gliomas.
    McDonald MF; Athukuri P; Anand A; Gopakumar S; Jalali A; Patel AJ; Rao G; Goodman JC; Lu HC; Mandel JJ
    Neurosurg Focus; 2022 Dec; 53(6):E16. PubMed ID: 36455273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas.
    Granberg KJ; Annala M; Lehtinen B; Kesseli J; Haapasalo J; Ruusuvuori P; Yli-Harja O; Visakorpi T; Haapasalo H; Nykter M; Zhang W
    Neuro Oncol; 2017 Sep; 19(9):1206-1216. PubMed ID: 28379477
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples.
    Kurobe M; Kojima T; Nishimura K; Kandori S; Kawahara T; Yoshino T; Ueno S; Iizumi Y; Mitsuzuka K; Arai Y; Tsuruta H; Habuchi T; Kobayashi T; Matsui Y; Ogawa O; Sugimoto M; Kakehi Y; Nagumo Y; Tsutsumi M; Oikawa T; Kikuchi K; Nishiyama H
    PLoS One; 2016; 11(12):e0165109. PubMed ID: 27930669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
    Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
    Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FGFR-TACC gene fusions in human glioma.
    Lasorella A; Sanson M; Iavarone A
    Neuro Oncol; 2017 Apr; 19(4):475-483. PubMed ID: 27852792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions.
    Mata DA; Benhamida JK; Lin AL; Vanderbilt CM; Yang SR; Villafania LB; Ferguson DC; Jonsson P; Miller AM; Tabar V; Brennan CW; Moss NS; Sill M; Benayed R; Mellinghoff IK; Rosenblum MK; Arcila ME; Ladanyi M; Bale TA
    Acta Neuropathol Commun; 2020 Nov; 8(1):186. PubMed ID: 33168106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features.
    Bielle F; Di Stefano AL; Meyronet D; Picca A; Villa C; Bernier M; Schmitt Y; Giry M; Rousseau A; Figarella-Branger D; Maurage CA; Uro-Coste E; Lasorella A; Iavarone A; Sanson M; Mokhtari K
    Brain Pathol; 2018 Sep; 28(5):674-683. PubMed ID: 28976058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.
    Parker BC; Annala MJ; Cogdell DE; Granberg KJ; Sun Y; Ji P; Li X; Gumin J; Zheng H; Hu L; Yli-Harja O; Haapasalo H; Visakorpi T; Liu X; Liu CG; Sawaya R; Fuller GN; Chen K; Lang FF; Nykter M; Zhang W
    J Clin Invest; 2013 Feb; 123(2):855-65. PubMed ID: 23298836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications.
    Dono A; El Achi H; Bundrant BE; Goli PS; Zhu P; Ozkizilkaya HI; Esquenazi Y; Ballester LY
    Cancer Biomark; 2023; 36(2):117-131. PubMed ID: 36530080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of FGFR3-TACC3 rearrangement in hematological malignancies with numerical chromosomal alteration.
    Banella C; Ginevrino M; Catalano G; Fabiani E; Falconi G; Divona M; Curzi P; Panetta P; Voso MT; Noguera NI
    Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):163-168. PubMed ID: 32199932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinico-pathological and epigenetic heterogeneity of diffuse gliomas with FGFR3::TACC3 fusion.
    Métais A; Tauziède-Espariat A; Garcia J; Appay R; Uro-Coste E; Meyronet D; Maurage CA; Vandenbos F; Rigau V; Chiforeanu DC; Pallud J; Senova S; Saffroy R; Colin C; Edjlali M; Varlet P; Figarella-Branger D;
    Acta Neuropathol Commun; 2023 Jan; 11(1):14. PubMed ID: 36647073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma.
    Gött H; Uhl E
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TARGET: A phase I/II open-label multicenter study to assess safety and efficacy of fexagratinib in patients with relapsed/refractory FGFR fusion-positive glioma.
    Picca A; Di Stefano AL; Savatovsky J; Ducray F; Chinot O; Moyal EC; Augereau P; Le Rhun E; Schmitt Y; Rousseaux N; Yepnang AMM; Estellat C; Charbonneau F; Letourneur Q; Branger DF; Meyronet D; Fardeau C; Mokhtari K; Bielle F; Iavarone A; Sanson M
    Neurooncol Adv; 2024; 6(1):vdae068. PubMed ID: 38813112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic FGFR3 gene fusions in bladder cancer.
    Williams SV; Hurst CD; Knowles MA
    Hum Mol Genet; 2013 Feb; 22(4):795-803. PubMed ID: 23175443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.
    Yuan L; Liu ZH; Lin ZR; Xu LH; Zhong Q; Zeng MS
    Cancer Biol Ther; 2014; 15(12):1613-21. PubMed ID: 25535896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma.
    Capelletti M; Dodge ME; Ercan D; Hammerman PS; Park SI; Kim J; Sasaki H; Jablons DM; Lipson D; Young L; Stephens PJ; Miller VA; Lindeman NI; Munir KJ; Richards WG; Jänne PA
    Clin Cancer Res; 2014 Dec; 20(24):6551-8. PubMed ID: 25294908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions.
    Di Stefano AL; Picca A; Saragoussi E; Bielle F; Ducray F; Villa C; Eoli M; Paterra R; Bellu L; Mathon B; Capelle L; Bourg V; Gloaguen A; Philippe C; Frouin V; Schmitt Y; Lerond J; Leclerc J; Lasorella A; Iavarone A; Mokhtari K; Savatovsky J; Alentorn A; Sanson M;
    Neuro Oncol; 2020 Nov; 22(11):1614-1624. PubMed ID: 32413119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.
    Ou SI; Horn L; Cruz M; Vafai D; Lovly CM; Spradlin A; Williamson MJ; Dagogo-Jack I; Johnson A; Miller VA; Gadgeel S; Ali SM; Schrock AB
    Lung Cancer; 2017 Sep; 111():61-64. PubMed ID: 28838400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.